+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Theravance Biopharma Inc (TBPH) - Financial and Strategic SWOT Analysis Review

Theravance Biopharma Inc (TBPH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Theravance Biopharma Inc (Theravance Biopharma) is a biopharmaceutical company that discovers, develops, and markets organ-selective medicines for the treatment of inflammation and immune system disorders and specializes in developing respiratory medicines. The company is investigating its pipeline candidates for the treatment of asthma; and neurogenic orthostatic hypotension (nOH). Theravance Biopharma has agreements with other pharmaceutical companies and holds economic interests in potential future payments made to Innoviva, Inc from Glaxo Group Limited or one of its affiliates. The company has subsidiaries in the US, Ireland, and the UK. Theravance Biopharma is headquartered in George Town, Cayman Islands, the UK.

Theravance Biopharma Inc Key Recent Developments

  • Feb 26, 2024: Theravance Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
  • Dec 21, 2023: Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors
  • Aug 07, 2023: Theravance Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Update
  • May 08, 2023: Theravance Biopharma reports first quarter 2023 financial results and provides business update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Theravance Biopharma Inc - Key Facts
  • Theravance Biopharma Inc - Key Employees
  • Theravance Biopharma Inc - Key Employee Biographies
  • Theravance Biopharma Inc - Major Products and Services
  • Theravance Biopharma Inc - History
  • Theravance Biopharma Inc - Company Statement
  • Theravance Biopharma Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Theravance Biopharma Inc - Business Description
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: US
  • Performance
  • R&D Overview
  • Theravance Biopharma Inc - Corporate Strategy
  • Theravance Biopharma Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Theravance Biopharma Inc - Strengths
  • Theravance Biopharma Inc - Weaknesses
  • Theravance Biopharma Inc - Opportunities
  • Theravance Biopharma Inc - Threats
  • Theravance Biopharma Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Theravance Biopharma Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Feb 26, 2024: Theravance Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
  • Dec 21, 2023: Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors
  • Aug 07, 2023: Theravance Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Update
  • May 08, 2023: Theravance Biopharma reports first quarter 2023 financial results and provides business update
  • Apr 11, 2023: Theravance Biopharma, Inc. Announces Appointment of Jim Kelly, Managing Director at Weiss Asset Management, to Board of Directors
  • Feb 27, 2023: Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update
  • Feb 21, 2023: Theravance Biopharma to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
  • Jan 09, 2023: Theravance Biopharma highlights 2022 accomplishments and 2023 Key Targets
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Theravance Biopharma Inc, Key Facts
  • Theravance Biopharma Inc, Key Employees
  • Theravance Biopharma Inc, Key Employee Biographies
  • Theravance Biopharma Inc, Major Products and Services
  • Theravance Biopharma Inc, History
  • Theravance Biopharma Inc, Subsidiaries
  • Theravance Biopharma Inc, Key Competitors
  • Theravance Biopharma Inc, Ratios based on current share price
  • Theravance Biopharma Inc, Annual Ratios
  • Theravance Biopharma Inc, Annual Ratios (Cont...1)
  • Theravance Biopharma Inc, Annual Ratios (Cont...2)
  • Theravance Biopharma Inc, Interim Ratios
  • Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Theravance Biopharma Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Theravance Biopharma Inc, Performance Chart (2019 - 2023)
  • Theravance Biopharma Inc, Ratio Charts
  • Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Sumitomo Pharma America Inc
  • Sanofi
  • Chiesi Farmaceutici SpA
  • Verona Pharma Plc
  • Regeneron Pharmaceuticals Inc
  • Hikma Pharmaceuticals Plc
  • AstraZeneca Plc
  • Synairgen Plc
  • Novartis AG
  • AstraZeneca Plc
  • Hikma Pharmaceuticals Plc
  • Innoviva Inc
  • Chiesi Farmaceutici SpA
  • Verona Pharma Plc
  • Sunovion Pharmaceuticals Inc
  • Synairgen Plc
  • Novartis AG